Letybo

Botulinum toxin type A, the active ingredient in Letybo, is a Botulinum toxin presented as a sterile injectable for intramuscular use. It temporarily relaxes targeted muscles and is used in therapeutic and aesthetic indications by blocking acetylcholine release at the neuromuscular junction, leading to temporary paralysis. The effect lasts several months, allowing repeat treatments as clinically indicated.

GNH USA supplies Letybo as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Botulinum toxin type A is employed in several neuromuscular and glandular disorders where temporary muscle relaxation or reduced secretion is desired.

- Cervical dystonia: reduces abnormal neck muscle contractions and associated pain. - Chronic migraine: decreases frequency of migraine attacks when injected in specific head muscles. - Upper limb spasticity: improves range of motion by relaxing overactive forearm muscles. - Hyperhidrosis: diminishes excessive sweating by inhibiting sweat gland activity. - Glabellar lines: smooths frown lines for cosmetic improvement.

Botulinum toxin type A may cause a range of adverse reactions, varying from mild to serious.

Common Side Effects: - Injection site pain: mild discomfort at the injection site. - Bruising: small hematoma around the needle entry point. - Headache: transient headache following treatment. - Flu‑like symptoms: mild fever or malaise. - Localized muscle weakness: temporary reduction in strength near the injection area.

Serious or Rare Side Effects: - Dysphagia: difficulty swallowing when neck muscles are affected. - Respiratory compromise: breathing difficulties if toxin spreads to respiratory muscles. - Allergic reactions: rash, itching, or anaphylaxis. - Systemic spread of toxin effect: generalized weakness or botulism‑like syndrome. - Vision changes: double vision or blurred sight.

When using Botulinum toxin type A, several precautions should be observed to ensure patient safety. - Pregnancy: safety not established; avoid unless clearly needed. - Breastfeeding: unknown safety; exercise caution. - Neuromuscular disorders: may exacerbate conditions such as myasthenia gravis. - Concurrent aminoglycoside antibiotics: increased risk of enhanced neuromuscular blockade. - Allergy to botulinum toxin: contraindicated in patients with known hypersensitivity. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Botulinum toxin type A can interact with other medications, affecting its safety and efficacy.

Major Interactions (Avoid): - Aminoglycoside antibiotics: may potentiate neuromuscular blockade. - Other botulinum toxin products: cumulative effect can increase toxicity. - Neuromuscular blocking agents: heightened risk of profound paralysis.

Moderate Interactions (Monitor Closely): - Anticholinergic agents: may influence muscle tone and response. - Calcium channel blockers: possible increase in muscle weakness. - Muscle relaxants: additive effect on muscle relaxation.